Abstract

This report summarized the discussion on: 

  • Routine PCV13 use among adults >65 years old: summary of evidence, cost‐effectiveness, and GRADE conclusions
  • Considerations for PCV13 use among adults and policy options
  • Recommendations for PCV13 use among adults
  • Agenda & Minutes
  • Americas
  • United States of America
  • Pneumococcal disease